Hashimoto, Kenji

Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist

Shirayama, Y., Yang, C., Zhang, J.-C., Ren, Q., Yao, W., & Hashimoto, K. (2015) · European Neuropsychopharmacology

Treatment of Major DepressionNerve injury and regeneration

Cited by 137

Brain-spleen axis in health and diseases: A review and future perspective

Wei, Y., Wang, T., Liao, L., Fan, X., Chang, L., & Hashimoto, K. (2022) · Brain Research Bulletin

Stress Responses and CortisolVagus Nerve Stimulation Research

Cited by 134

Decreased serum levels of transforming growth factor-β1 in patients with autism

Okada, K., Hashimoto, K., Iwata, Y., Nakamura, K., Tsujii, M., Tsuchiya, K. J., Sekine, Y., Suda, S., Suzuki, K., Sugihara, G.-I., et al. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry

Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Cited by 132

An update on ketamine and its two enantiomers as rapid-acting antidepressants

Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 132

Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys

Hashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H. (2017) · European Archives of Psychiatry and Clinical Neuroscience

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 127

Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1

Zhang, K., Yang, C., Chang, L., Sakamoto, A., Suzuki, T., Fujita, Y., Qu, Y., Wang, S., Pu, Y., Tan, Y., et al. (2020) · Translational Psychiatry

Treatment of Major DepressionTryptophan and brain disorders

Cited by 119

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia

Shiina, A., Kanahara, N., Sasaki, T., Oda, Y., Hashimoto, T., Hasegawa, T., Yoshida, T., Iyo, M., & Hashimoto, K. (2015) · Clinical Psychopharmacology and Neuroscience

Schizophrenia research and treatmentTryptophan and brain disorders

Cited by 107

(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice

Yamaguchi, J.-I., Toki, H., Qu, Y., Yang, C., Koike, H., Hashimoto, K., Mizuno-Yasuhira, A., & Chaki, S. (2018) · Neuropsychopharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 105

Retracted: Regional Differences in Brain-Derived Neurotrophic Factor Levels and Dendritic Spine Density Confer Resilience to Inescapable Stress

Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology

Stress Responses and CortisolNeurotransmitter Receptor Influence on Behavior

Cited by 103

Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine.

Yamamori, H., Hashimoto, R., Ishima, T., Kishi, F., Yasuda, Y., Ohi, K., Fujimoto, M., Umeda-Yano, S., Ito, A., Hashimoto, K., et al. (2013) · Neuroscience Letters

Schizophrenia research and treatmentTryptophan and brain disorders

Cited by 101

Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future Perspective

Hashimoto, K. (2018) · Frontiers in Pharmacology

Tryptophan and brain disordersTreatment of Major Depression

Cited by 98

Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis

Tadokoro, S., Okamura, N., Sekine, Y., Kanahara, N., Hashimoto, K., & Iyo, M. (2012) · Schizophrenia Bulletin

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 92

(R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism

Ago, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., et al. (2019) · International Journal of Neuropsychopharmacology

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 92

Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression

Yang, B., Zhang, J.-C., Han, M., Yao, W., Yang, C., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K. (2016) · Psychopharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 91

Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine

Yang, C., Han, M., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2016) · Psychiatry Research

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 91

Potentiation of the NMDA receptor‐mediated responses through the activation of the glycine site by microglia secreting soluble factors

Hayashi, Y., Ishibashi, H., Hashimoto, K., & Nakanishi, H. (2006) · Glia

Neuroscience and Neuropharmacology ResearchNeuroinflammation and Neurodegeneration Mechanisms

Cited by 90

Abnormality in glutamine–glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study

Hashimoto, K., Bruno, D., Nierenberg, J., Marmar, C. R., Zetterberg, H., Blennow, K., & Pomara, N. (2016) · Translational Psychiatry

Treatment of Major DepressionTryptophan and brain disorders

Cited by 90

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant

Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. (2016) · Neuroscience Bulletin

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 80

Antibiotic-Induced Microbiome Depletion Protects against MPTP-Induced Dopaminergic Neurotoxicity in the Brain

Pu, Y., Chang, L., Qu, Y., Wang, S., Zhang, K., & Hashimoto, K. (2019) · Aging

Parkinson's Disease Mechanisms and TreatmentsGut microbiota and health

Cited by 80

Magnetic Resonance Spectroscopy Study of the Antioxidant Defense System in Schizophrenia

Matsuzawa, D., & Hashimoto, K. (2011) · Antioxidants & Redox Signaling

Advanced MRI Techniques and ApplicationsSchizophrenia research and treatment

Cited by 79

Targeting of NMDA receptors in the treatment of major depression

Dang, Y.-H., Ma, X.-C., Zhang, J.-C., Ren, Q., Wu, J., Gao, C.-G., & Hashimoto, K. (2014) · Current Pharmaceutical Design

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 79

Lack of Opioid System in the Antidepressant Actions of Ketamine

Zhang, K., & Hashimoto, K. (2019) · Biological Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 71

Regional differences in dendritic spine density confer resilience to chronic social defeat stress

Qu, Y., Yang, C., Ren, Q., Ma, M., Dong, C., & Hashimoto, K. (2018) · Acta Neuropsychiatrica

Neuroscience and Neuropharmacology ResearchStress Responses and Cortisol

Cited by 68

Keap1-Nrf2 signaling pathway confers resilience versus susceptibility to inescapable electric stress

Zhang, J.-C., Yao, W., Dong, C., Han, M., Shirayama, Y., & Hashimoto, K. (2018) · European Archives of Psychiatry and Clinical Neuroscience

Genomics, phytochemicals, and oxidative stressTreatment of Major Depression

Cited by 66